|Status: One Wales interim decision|
Using the agreed starting and stopping criteria, azacitidine can be made available within NHS Wales for the treatment of progressive angioimmunoblastic T-cell lymphoma.
The risks and benefits of the off-label use of azacitidine for this indication should be clearly stated and discussed with the patient to allow informed consent.
In July 2020 OWMAG recommended this treatment in NHS Wales, in September 2023 there was a review of the recommendation. OWMAG found nothing new that effects the original decision.
This advice will be reviewed after 2 years or earlier if new evidence becomes available.
|Formulation||Powder for suspension for injection|
For the treatment of progressive angioimmunoblastic T-cell lymphoma
|BNF chapter||Malignant disease & immunosuppression|
|Submission type||One Wales|
|Status||One Wales interim decision|
|Date of issue||23/07/2020|
|Date of last review||September 2023|